Anti-PD-1 monoclonal antibody combined CD3-retronectin activated T cell in heavy-treated renal cell cancer.

作者：Lingdi, Zhao; Wei, Li; Yonghao, Yang; Yong, Zhang; Xiubao, Ren; Quanli, Gao

来源：Journal of Clinical Oncology, 2017, 35(15_suppl): 3047-3047.

DOI：10.1200/jco.2017.35.15_suppl.3047

<jats:p> 3047 </jats:p><jats:p> Background: Metastatic renal cell carcinoma (MRCC) has a poor prognosis after failure of multitargeted tyrosine kinase inhibitors. New immunomodulators, such as anti-programmed death (PD)-1 antibody drugs, have made progress in the treatment of MRCC, but their objective response rate is only about 25%. Therefore, it is important to enhance the response rate of anti-PD-1 therapy. Methods: Patients with MRCC were eligible if they were failed to at least one kinase inhibitors, ECOG PS 0-2. Patients received nivolumab (2mg/kg, q2w) or keytruda ( 2mg/kg, q3w), followed by CD3-retronectin activated T cell, and the total number of CD3-retronectin activated T cell each time was about 5×10<jats:sup>9</jats:sup>/L. The primary objective was to determine the objective response rate, secondary objectives included time to symptom relief, time to efficacy, safety. Results: 8 pts were enrolled (median age 58 [31-79], male 6). Pts had received a median of 2 (1-4) prior regimens. To date there is 2 patients that the efficacy can not be evaluated. The other 6 pts got remission (3 complete remission and 3 partial remission), the median time to efficacy was 10 weeks (6-12 weeks) and the time to symptom relief was 4 weeks (3-6 weeks). There was no grade 3/4 adverse effects. family:'';font-size:12.0000pt;mso-font-kerning:1.0000pt;" &gt; 10<jats:sup>9</jats:sup>/L. The primary objective was to determine the objective response rate, secondary objectives included time to symptom relief, time to efficacy, safety. Conclusions: CD3-retronectin activated T cell might improve the efficacy of anti-PD-1 therapy without increasing the side effects. This combination therapy has many implications in the age of immunotherapy, and should be explored across cancer types. mily:'';font-size:12.0000pt;mso-font-kerning:1.0000pt;" &gt; 10<jats:sup>9</jats:sup>/L. The primary objective was to determine the objective response rate, secondary objectives included time to symptom relief, time to efficacy, safety. </jats:p>

• 出版日期2017-5-20
• 单位天津医科大学; 郑州大学